138 related articles for article (PubMed ID: 7495962)
1. Hepatitis A virus and blood products: virus validation studies.
Lemon SM
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S20-2. PubMed ID: 7495962
[TBL] [Abstract][Full Text] [Related]
2. Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates.
Hamman J; Zou J; Horowitz B
Vox Sang; 1994; 67 Suppl 1():72-6; discussion 77. PubMed ID: 8091742
[TBL] [Abstract][Full Text] [Related]
3. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
[TBL] [Abstract][Full Text] [Related]
4. Virus validation experiments on the production process of OCTAVI SDPlus.
Biesert L; Lemon S; Suhartono H; Wang L; Rübsamen H
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S48-54. PubMed ID: 7495968
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.
Robertson BH; Alter MJ; Bell BP; Evatt B; McCaustland KA; Shapiro CN; Sinha SD; Souci JM
Biologicals; 1998 Jun; 26(2):95-9. PubMed ID: 9811512
[TBL] [Abstract][Full Text] [Related]
7. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products.
Lemon SM
Vox Sang; 1994; 67 Suppl 4():19-23; discussion 24-6. PubMed ID: 7831865
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis A virus and polymerase chain reaction amplification: methodology and results.
Robertson BH; Normann A; Graff J; Flehmig B; Friedberg D; Shouval D
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S27-31. PubMed ID: 7495964
[TBL] [Abstract][Full Text] [Related]
9. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis A virus infections associated with clotting factor concentrate in the United States.
Soucie JM; Robertson BH; Bell BP; McCaustland KA; Evatt BL
Transfusion; 1998 Jun; 38(6):573-9. PubMed ID: 9661691
[TBL] [Abstract][Full Text] [Related]
11. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool.
Chudy M; Budek I; Keller-Stanislawski B; McCaustland KA; Neidhold S; Robertson BH; Nübling CM; Seitz R; Löwer J
J Med Virol; 1999 Feb; 57(2):91-9. PubMed ID: 9892390
[TBL] [Abstract][Full Text] [Related]
12. Development and biochemical characterization of a double-virus-inactivated factor VIII preparation.
Robinson S; Schwinn H; Josic D; Nur I; Stadler M; Bal F; Gehringer W; Schütz R
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S40-7. PubMed ID: 7495967
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of hepatitis A virus by heat treatment in aqueous solution.
Murphy P; Nowak T; Lemon SM; Hilfenhaus J
J Med Virol; 1993 Sep; 41(1):61-4. PubMed ID: 8228940
[TBL] [Abstract][Full Text] [Related]
14. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
15. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
[TBL] [Abstract][Full Text] [Related]
16. Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin.
Murozuka T; Aoki M; Kimura N; Sotoyama K; Abe I; Izumi H; Emura H; Takeda Y; Nanakawa H; Katsubayashi Y; Takeuchi T; Ito H; Hirakawa S; Mitsunaga S; Tadokoro K; Kanemitsu K; Miyamoto M; Yamanaka R; Nishioka K
Vox Sang; 1999; 76(3):181-6. PubMed ID: 10341335
[TBL] [Abstract][Full Text] [Related]
17. Virus-binding activity of fibronectin: masking of hepatitis A virus.
Seelig R; Pott G; Seelig HP; Liehr H; Metzger P; Waldherr R
J Virol Methods; 1984 Jul; 8(4):335-47. PubMed ID: 6088567
[TBL] [Abstract][Full Text] [Related]
18. Absence of hepatitis A virus transmission by high-purity solvent detergent treated coagulation factor concentrates in Scottish haemophiliacs.
Watson HG; Ludlam CA; McOmish F; Dennis R; Hart H; Simmonds P
Br J Haematol; 1995 Jan; 89(1):214-6. PubMed ID: 7833268
[TBL] [Abstract][Full Text] [Related]
19. Transmission of hepatitis A by transfusion of blood products.
Sherertz RJ; Russell BA; Reuman PD
Arch Intern Med; 1984 Aug; 144(8):1579-80. PubMed ID: 6087755
[TBL] [Abstract][Full Text] [Related]
20. Review of the hepatitis A epidemics in hemophiliacs in Europe.
Vermylen J; Peerlinck K
Vox Sang; 1994; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
